European Perinatal Health Report Released By EURO-PERISTAT Project Promoting
healthy pregnancy and safe childbirth is a goal of all European
health care systems. Despite progress in recent decades, mothers and their babies are still very much at risk during the perinatal period, which covers pregnancy, delivery, and the postpartum. The European Perinatal
Health Report released by the EURO-PERISTAT project is the most comprehensive report on the subject to date and takes a new approach to
health reporting.
Source: www.medicalnewstoday.comInexperienced Prostitutes Most At Risk Of Sexual Infections Less experienced prostitutes are more likely to have sexually transmitted infections (STIs). A study of more than a thousand female sex workers in Cambodia, reported in the open access journal BMC Infectious Diseases, has shown that girls who were new to the sex industry were twice as likely to have gonorrhoea or chlamydia.
Source: www.medicalnewstoday.comMajor Pain Research Funding Decline At NIH Federal funding for pain research is declining sharply, more than 9 percent a year since 2003, according to a new study published in The Journal of Pain. Pain research, as a result, now accounts for only 0.6 percent of all grants awarded by the National Institutes of
Health (NIH), despite the high prevalence of chronic pain in the U.S.
Source: www.medicalnewstoday.comEngland To Offer Nonprescription Oral Contraception Under Pilot Programs In London Area England plans to launch two pilot programs in the London area that will provide women with non
prescription access to birth control pills, the PA/Google.com reports.
Source: www.medicalnewstoday.comPain Therapeutics Receives Complete Response Letter From FDA For REMOXY(R) DURECT Corporation (Nasdaq: DRRX) reported that Pain Therapeutics, Inc. (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of oxycodone. Based on its review, the FDA has determined that the NDA is not approved in its present form. According to King Pharmaceuticals, Inc.
Source: www.medicalnewstoday.comTyverb(R)/Tykerb(R) Plus Letrozole Significantly Delayed Disease Progression In Post-menopausal Women With ErbB2 Positive Metastatic Breast Cancer New results from a study in metastatic breast cancer showed that the combination of Tyverb®/Tykerb® (lapatinib) plus letrozole as a first line treatment regimen provided a significant improvement in delaying disease progression when compared to treatment with Femara® (letrozole) alone.[i] In the study, women diagnosed with post-menopausal, hormone receptor positive (HR+) and ErbB2 positive metastatic breast cancer experienced a 5.
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
